Share Prices & Company Research

Market News

14 Jul 2020 | 09:07

Clinigen FY revenues continue to rise, profit growth slowed by Covid-19

(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pandemic and the launch of a low-cost competitor to its Foscavir drug. Although 2021 was said to be the lower end of guidance, Clinigen still anticipates medium-term organic profit growth will be 5-10%, the company said on Tuesday

Clinigen highlighted that the effect of Covid-19, expected to be felt in the first quarter of the current year, would result in underlying earnings taking a hit of roughly £8m - primarily related to the disrupted launch of its cancer treatment, Proleukin.

Revenues for fiscal 2020 were estimated to have grown roughly 17% at constant currencies - or 13% on a gross reported basis.

The AIM-listed group added that underlying earnings were predicted to have grown at least 29% year-on-year, while cash conversion was said to have returned to "normal levels" in the second half - with net debt of £312m.

Chief executive Shaun Chilton said: "We continue to see organic growth in line with our medium-term guidance at this early stage of the new financial year, despite Covid-19 and expected competitive pressure to Foscavir.

"As we look beyond FY21, we see growth significantly accelerating as we onboard new asset Erwinase and we continue to gain share in the end-markets we serve."

As of 0905 BST, Clinigen shares had sunk 10.82% to 709p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 15th January 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.